Global Guide of Coming Off-patent Agrochemical Active Ingredients Edition (5)

Global Guide of Coming Off-patent Agrochemical Active Ingredients Edition (5)

Table of Contents

Executive summary 1
Methodology and scope 4
1 Profiles of coming off-patent herbicides 9
1.1 Aminopyralid 9
1.2 Flucetosulfuron 14
1.3 Flufenpyr-ethyl 16
1.4 Metamifop 18
1.5 Orthosulfamuron . 21
1.6 Pinoxaden . 24
1.7 Pyrasulfotole 30
1.8 Pyroxasulfone 33
1.9 Pyroxsulam 35
1.10 Saflufenacil 41
1.11 Tembotrione 43
1.12 Thiencarbazone-methyl 48
1.13 Topramezone 52
2 Profiles of coming off-patent insecticides 57
2.1 Chlorantraniliprole 57
2.2 Flubendiamide 61
2.3 Metofluthrin 64
2.4 Pyrifluquinazon 67
2.5 Spirotetramat 68
2.6 Cyantraniliprole 76
2.7 Cyflumetofen 79
3 Profiles of coming off-patent fungicides 83
3.1 Amisulbrom 83
3.2 Fenpyrazamine . 86
3.3 Fluopicolide 88
3.4 Isotianil ... 93
3.5 Mandipropamid . 95
3.6 Metrafenone 102
3.7 Penflufen 107
3.8 Valifenalate 110
3.9 Bixafen .. 113
3.10 Fluopyram 118
3.11 Isopyrazam 123
3.12 Sedaxane 127
4 Others 132
4.1 Cyprosulfamide 132

LIST OF TABLES
Table 1.1-1 Patent information of aminopyralid in some countries/regions, as of July 2018
Table 1.1-2 Registration information of aminopyralid in China, as of July 2018
Table 1.1-3 Registration information of aminopyralid in Finland, as of July 2018
Table 1.1-4 Registration information of aminopyralid in Denmark, as of July 2018
Table 1.1-5 Registration information of aminopyralid in Canada, as of July 2018
Table 1.1-6 Registration information of aminopyralid in France, as of July 2018
Table 1.1-7 Registration information of aminopyralid in Uruguay, as of July 2018
Table 1.1-8 Registration information of aminopyralid in Australia, as of July 2018
Table 1.1-9 Registration information of aminopyralid in Switzerland, as of July 2018
Table 1.1-10 Registration information of aminopyralid in Argentina, as of July 2018
Table 1.1-11 Registration information of aminopyralid in South Africa, as of July 2018
Table 1.1-12 Registration information of aminopyralid in Belgium, as of July 2018
Table 1.1-13 Registration information of aminopyralid in Greece, as of July 2018
Table 1.2-1 Patent information of flucetosulfuron in some countries/regions, as of July 2018
Table 1.2-2 Registration information of flucetosulfuron in China, as of July 2018
Table 1.3-1 Patent information of flufenpyr-ethyl in some countries/regions, as of July 2018
Table 1.4-1 Patent information of metamifop in some countries/regions, as of July 2018
Table 1.4-2 Registration information of metamifop in China, as of July 2018
Table 1.4-3 Registration information of metamifop in Uruguay, as of July 2018
Table 1.5-1 Patent information of orthosulfamuron in some countries/regions, as of July 2018
Table 1.5-2 Registration information of orthosulfamuron in China, as of July 2018
Table 1.5-3 Registration information of orthosulfamuron in Brazil, as of July 2018
Table 1.6-1 Patent information of pinoxaden in some countries/regions, as of July 2018
Table 1.6-2 Registration information of pinoxaden in Argentina, as of July 2018
Table 1.6-3 Registration information of pinoxaden in South Africa, as of July 2018
Table 1.6-4 Registration information of pinoxaden in Australia, as of July 2018
Table 1.6-5 Registration information of pinoxaden in Belgium, as of July 2018
Table 1.6-6 Registration information of pinoxaden in Canada, as of July 2018
Table 1.6-7 Registration information of pinoxaden in Chile, as of July 2018
Table 1.6-8 Registration information of pinoxaden in China, as of July 2018
Table 1.6-9 Registration information of pinoxaden in Finland, as of July 2018
Table 1.6-10 Registration information of pinoxaden in France, as of July 2018
Table 1.6-11 Registration information of pinoxaden in Greece, as of July 2018
Table 1.6-12 Registration information of pinoxaden in the Netherlands, as of July 2018
Table 1.6-13 Registration information of pinoxaden in Switzerland, as of July 2018
Table 1.6-14 Registration information of pinoxaden in Uruguay, as of July 2018
Table 1.7-1 Patent information of pyrasulfotole in some countries/regions, as of July 2018
Table 1.7-2 Registration information of pyrasulfotole in Canada, as of July 2018
Table 1.7-3 Registration information of pyrasulfotole in Australia, as of July 2018
Table 1.7-4 Registration information of pyrasulfotole in South Africa, as of July 2018
Table 1.8-1 Patent information of pyroxasulfone in some countries/regions, as of July 2018
Table 1.8-2 Registration information of pyroxasulfone in Canada, as of July 2018
Table 1.8-3 Registration information of pyroxasulfone in Australia, as of July 2018
Table 1.8-4 Registration information of pyroxasulfone in South Africa, as of July 2018
Table 1.9-1 Patent information of pyroxsulam in some countries/regions, as of July 2018
Table 1.9-2 Registration information of pyroxsulam in China, as of July 2018
Table 1.9-3 Registration information of pyroxsulam in Belgium, as of July 2018
Table 1.9-4 Registration information of pyroxsulam in Brazil, as of July 2018
Table 1.9-5 Registration information of pyroxsulam in Canada, as of July 2018
Table 1.9-6 Registration information of pyroxsulam in France, as of July 2018
Table 1.9-7 Registration information of pyroxsulam in the Netherlands, as of July 2018
Table 1.9-8 Registration information of pyroxsulam in Australia, as of July 2018
Table 1.9-9 Registration information of pyroxsulam in Switzerland, as of July 2018
Table 1.9-10 Registration information of pyroxsulam in Denmark, as of July 2018
Table 1.9-11 Registration information of pyroxsulam in Finland, as of July 2018
Table 1.9-12 Registration information of pyroxsulam in Greece, as of July 2018
Table 1.9-13 Registration information of pyroxsulam in South Africa, as of July 2018
Table 1.10-1 Patent information of saflufenacil in some countries/regions, as of July 2018
Table 1.10-2 Registration information of saflufenacil in China, as of July 2018
Table 1.10-3 Registration information of saflufenacil in Brazil, as of July 2018
Table 1.10-4 Registration information of saflufenacil in Canada, as of July 2018
Table 1.10-5 Registration information of saflufenacil in Uruguay, as of July 2018
Table 1.10-6 Registration information of saflufenacil in Australia, as of July 2018
Table 1.10-7 Registration information of saflufenacil in Chile, as of July 2018
Table 1.10-8 Registration information of saflufenacil in Argentina, as of July 2018
Table 1.11-1 Patent information of tembotrione in some countries/regions, as of July 2018
Table 1.11-2 Registration information of tembotrione in Belgium, as of July 2018
Table 1.11-3 Registration information of tembotrione in South Africa, as of July 2018
Table 1.11-4 Registration information of tembotrione in Canada, as of July 2018
Table 1.11-5 Registration information of tembotrione in Chile, as of July 2018
Table 1.11-6 Registration information of tembotrione in France, as of July 2018
Table 1.11-7 Registration information of tembotrione in the Netherlands, as of July 2018
Table 1.11-8 Registration information of tembotrione in Switzerland, as of July 2018
Table 1.11-9 Registration information of tembotrione in Greece, as of July 2018
Table 1.12-1 Patent information of thiencarbazone-methyl in some countries/regions, as of
July 2018
Table 1.12-2 Registration information of thiencarbazone-methyl in Belgium, as of July 2018
Table 1.12-3 Registration information of thiencarbazone-methyl in Canada, as of July 2018
Table 1.12-4 Registration information of thiencarbazone-methyl in France, as of July 2018
Table 1.12-5 Registration information of thiencarbazone-methyl in the Netherlands, as of July
2018
Table 1.12-6 Registration information of thiencarbazone-methyl in Uruguay, as of July 2018
Table 1.12-7 Registration information of thiencarbazone-methyl in China, as of July 2018
Table 1.12-8 Registration information of thiencarbazone-methyl in Denmark, as of July 2018
Table 1.13-1 Patent information of topramezone in some countries/regions, as of July 2018
Table 1.13-2 Registration information of topramezone in Argentina, as of July 2018
Table 1.13-3 Registration information of topramezone in South Africa, as of July 2018
Table 1.13-4 Registration information of topramezone in Canada, as of July 2018
Table 1.13-5 Registration information of topramezone in Chile, as of July 2018
Table 1.13-6 Registration information of topramezone in China, as of July 2018
Table 1.13-7 Registration information of topramezone in Australia, as of July 2018
Table 1.13-8 Registration information of topramezone in Greece, as of July 2018
Table 2.1-1 Patent information of chlorantraniliprole in some countries/regions, as of July 2018
Table 2.1-2 Registration information of chlorantraniliprole in China, as of July 2018
Table 2.1-3 Registration information of chlorantraniliprole in Canada, as of July 2018
Table 2.1-4 Registration information of chlorantraniliprole in France, as of July 2018
Table 2.1-5 Registration information of chlorantraniliprole in the Netherlands, as of July 2018
Table 2.1-6 Registration information of chlorantraniliprole in Australia, as of July 2018
Table 2.1-7 Registration information of chlorantraniliprole in Switzerland, as of July 2018
Table 2.1-8 Registration information of chlorantraniliprole in South Africa, as of July 2018
Table 2.1-9 Registration information of chlorantraniliprole in Greece, as of July 2018
Table 2.2-1 Patent information of flubendiamide in some countries/regions, as of July 2018
Table 2.2-2 Registration information of flubendiamide in Argentina, as of July 2018
Table 2.2-3 Registration information of flubendiamide in Australia, as of July 2018
Table 2.2-4 Registration information of flubendiamide in South Africa, as of July 2018
Table 2.2-5 Registration information of flubendiamide in Chile, as of July 2018
Table 2.2-6 Registration information of flubendiamide in China, as of July 2018
Table 2.2-7 Registration information of flubendiamide in Uruguay, as of July 2018
Table 2.3-1 Patent information of metofluthrin in some countries/regions, as of July 2018
Table 2.3-2 Registration information of metofluthrin in Australia, as of July 2018
Table 2.3-3 Registration information of metofluthrin in Canada, as of July 2018
Table 2.3-4 Registration information of metofluthrin in China, as of July 2018
Table 2.3-5 Registration information of metofluthrin in the Netherlands, as of July 2018
Table 2.3-6 Registration information of metofluthrin in South Africa, as of July 2018
Table 2.4-1 Patent information of pyrifluquinazon in some countries/regions, as of July 2018
Table 2.5-1 Patent information of spirotetramat in some countries/regions, as of July 2018
Table 2.5-2 Registration information of spirotetramat in Argentina, as of July 2018
Table 2.5-3 Registration information of spirotetramat in Australia, as of July 2018
Table 2.5-4 Registration information of spirotetramat in Denmark, as of July 2018
Table 2.5-5 Registration information of spirotetramat in South Africa, as of July 2018
Table 2.5-6 Registration information of spirotetramat in Belgium, as of July 2018
Table 2.5-7 Registration information of spirotetramat in Canada, as of July 2018
Table 2.5-8 Registration information of spirotetramat in Chile, as of July 2018
Table 2.5-9 Registration information of spirotetramat in China, as of July 2018
Table 2.5-10 Registration information of spirotetramat in France, as of July 2018
Table 2.5-11 Registration information of spirotetramat in Greece, as of July 2018
Table 2.5-12 Registration information of spirotetramat in the Netherlands, as of July 2018
Table 2.5-13 Registration information of spirotetramat in Uruguay, as of July 2018
Table 2.5-14 Registration information of spirotetramat in Switzerland, as of July 2018
Table 2.5-15 Registration information of spirotetramat in Finland, as of July 2018
Table 2.6-1 Patent information of cyantraniliprole in some countries/regions, as of July 2018
Table 2.6-2 Registration information of cyantraniliprole in China, as of July 2018
Table 2.6-3 Registration information of cyantraniliprole in Canada, as of July 2018
Table 2.6-4 Registration information of cyantraniliprole in Australia, as of July 2018
Table 2.6-5 Registration information of cyantraniliprole in the Netherlands, as of July 2018
Table 2.6-6 Registration information of cyantraniliprole in Belgium, as of July 2018
Table 2.6-7 Registration information of cyantraniliprole in Argentina, as of July 2018
Table 2.7-1 Patent informulation of cyflumetofen in some countries/regions, as of July 2018
Table 2.7-2 Registration information of cyflumetofen in China, as of July 2018
Table 2.7-3 Registration information of cyflumetofen in Brazil, as of July 2018
Table 2.7-4 Registration information of cyflumetofen in Canada, as of July 2018
Table 2.7-5 Registration information of cyflumetofen in the Netherlands, as of July 2018
Table 2.7-6 Registration information of cyflumetofen in Belgium, as of July 2018
Table 2.7-7 Registration information of cyflumetofen in Argentina, as of July 2018
Table 3.1-1 Patent information of amisulbrom in some countries/regions, as of July 2018
Table 3.1-2 Registration information of amisulbrom in Belgium, as of July 2018
Table 3.1-3 Registration information of amisulbrom in France, as of July 2018
Table 3.1-4 Registration information of amisulbrom in Finland, as of July 2018
Table 3.1-5 Registration information of amisulbrom in the Netherlands, as of July 2018
Table 3.1-6 Registration information of amisulbrom in Switzerland, as of July 2018
Table 3.1-7 Registration information of amisulbrom in Australia, as of July 2018
Table 3.2-1 Patent information of fenpyrazamine in some countries/regions, as of July 2018
Table 3.2-2 Registration information of fenpyrazamine in Australia, as of July 2018
Table 3.2-3 Registration information of fenpyrazamine in Chile, as of July 2018
Table 3.2-4 Registration information of fenpyrazamine in Denmark, as of July 2018
Table 3.2-5 Registration information of fenpyrazamine in Belgium, as of July 2018
Table 3.2-6 Registration information of fenpyrazamine in France, as of July 2018
Table 3.2-7 Registration information of fenpyrazamine in the Netherlands, as of July 2018
Table 3.2-8 Registration information of fenpyrazamine in Finland, as of July 2018
Table 3.2-9 Registration information of fenpyrazamine in Switzerland, as of July 2018
Table 3.3-1 Patent information of fluopicolide in some countries/regions, as of July 2018
Table 3.3-2 Registration information of fluopicolide in Argentina, as of July 2018
Table 3.3-3 Registration information of fluopicolide in Australia, as of July 2018
Table 3.3-4 Registration information of fluopicolide in South Africa, as of July 2018
Table 3.3-5 Registration information of fluopicolide in Belgium, as of July 2018
Table 3.3-6 Registration information of fluopicolide in Brazil, as of July 2018
Table 3.3-7 Registration information of fluopicolide in Canada, as of July 2018
Table 3.3-8 Registration information of fluopicolide in Chile, as of July 2018
Table 3.3-9 Registration information of fluopicolide in China, as of July 2018
Table 3.3-10 Registration information of fluopicolide in Finland, as of July 2018
Table 3.3-11 Registration information of fluopicolide in France, as of July 2018
Table 3.3-12 Registration information of fluopicolide in the Netherlands, as of July 2018
Table 3.3-13 Registration information of fluopicolide in Switzerland, as of July 2018
Table 3.3-14 Registration information of fluopicolide in Uruguay, as of July 2018
Table 3.4-1 Patent information of isotianil in some countries/regions, as of July 2018
Table 3.4-2 Registration information of isotianil in China, as of July 2018
Table 3.5-1 Patent information of mandipropamid in some countries/regions, as of July 2018
Table 3.5-2 Registration information of mandipropamid in Belgium, as of July 2018
Table 3.5-3 Registration information of mandipropamid in Brazil, as of July 2018
Table 3.5-4 Registration information of mandipropamid in China, as of July 2018
Table 3.5-5 Registration information of mandipropamid in Canada, as of July 2018
Table 3.5-6 Registration information of mandipropamid in France, as of July 2018
Table 3.5-7 Registration information of mandipropamid in Finland, as of July 2018
Table 3.5-8 Registration information of mandipropamid in the Netherlands, as of July 2018
Table 3.5-9 Registration information of mandipropamid in Australia, as of July 2018
Table 3.5-10 Registration information of mandipropamid in Switzerland, as of July 2018
Table 3.5-11 Registration information of mandipropamid in Denmark, as of July 2018
Table 3.5-12 Registration information of mandipropamid in Chile, as of July 2018
Table 3.5-13 Registration information of mandipropamid in Argentina, as of July 2018
Table 3.5-14 Registration information of mandipropamid in South Africa, as of July 2018
Table 3.5-15 Registration information of mandipropamid in Greece, as of July 2018
Table 3.6-1 Patent information of metrafenone in some countries/regions, as of July 2018
Table 3.6-2 Registration information of metrafenone in Australia, as of July 2018
Table 3.6-3 Registration information of metrafenone in Argentina, as of July 2018
Table 3.6-4 Registration information of metrafenone in Denmark, as of July 2018
Table 3.6-5 Registration information of metrafenone in South Africa, as of July 2018
Table 3.6-6 Registration information of metrafenone in Belgium, as of July 2018
Table 3.6-7 Registration information of metrafenone in Canada, as of July 2018
Table 3.6-8 Registration information of metrafenone in Chile, as of July 2018
Table 3.6-9 Registration information of metrafenone in Switzerland, as of July 2018
Table 3.6-10 Registration information of metrafenone in France, as of July 2018
Table 3.6-11 Registration information of metrafenone in Greece, as of July 2018
Table 3.7-1 Patent information of penflufen in some countries/regions, as of July 2018
Table 3.7-2 Registration information of penflufen in Canada, as of July 2018
Table 3.7-3 Registration information of penflufen in the Netherlands, as of July 2018
Table 3.7-4 Registration information of penflufen in Australia, as of July 2018
Table 3.7-5 Registration information of penflufen in Finland, as of July 2018
Table 3.7-6 Registration information of penflufen in Belgium, as of July 2018
Table 3.7-7 Registration information of penflufen in Chile, as of July 2018
Table 3.8-1 Patent information of valifenalate in some countries/regions, as of July 2018
Table 3.8-2 Registration information of valifenalate in Belgium, as of July 2018
Table 3.8-3 Registration information of valifenalate in France, as of July 2018
Table 3.8-4 Registration information of valifenalate in Switzerland, as of July 2018
Table 3.8-5 Registration information of valifenalate in Chile, as of July 2018
Table 3.9-1 Patent information of bixafen in some countries/regions, as of July 2018
Table 3.9-2 Registration information of bixafen in Argentina, as of July 2018
Table 3.9-3 Registration information of bixafen in Australia, as of July 2018
Table 3.9-4 Registration information of bixafen in Belgium, as of July 2018
Table 3.9-5 Registration information of bixafen in Chile, as of July 2018
Table 3.9-6 Registration information of bixafen in Denmark, as of July 2018
Table 3.9-7 Registration information of bixafen in Finland, as of July 2018
Table 3.9-8 Registration information of bixafen in France, as of July 2018
Table 3.9-9 Registration information of bixafen in the Netherlands, as of July 2018
Table 3.9-10 Registration information of bixafen in South Africa, as of July 2018
Table 3.9-11 Registration information of bixafen in Switzerland, as of July 2018
Table 3.10-1 Patent information of fluopyram in some countries/regions, as of July 2018
Table 3.10-2 Registration information of fluopyram in Australia, as of July 2018
Table 3.10-3 Registration information of fluopyram in Belgium, as of July 2018
Table 3.10-4 Registration information of fluopyram in Canada, as of July 2018
Table 3.10-5 Registration information of fluopyram in China, as of July 2018
Table 3.10-6 Registration information of fluopyram in Denmark, as of July 2018
Table 3.10-7 Registration information of fluopyram in Finland, as of July 2018
Table 3.10-8 Registration information of fluopyram in France, as of July 2018
Table 3.10-9 Registration information of fluopyram in Greece, as of July 2018
Table 3.10-10 Registration information of fluopyram in the Netherlands, as of July 2018
Table 3.10-11 Registration information of fluopyram in South Africa, as of July 2018
Table 3.10-12 Registration information of fluopyram in Switzerland, as of July 2018
Table 3.11-1 Patent information of isopyrazam in some countries/regions, as of July 2018
Table 3.11-2 Registration information of isopyrazam in Argentina, as of July 2018
Table 3.11-3 Registration information of isopyrazam in Australia, as of July 2018
Table 3.11-4 Registration information of isopyrazam in Belgium, as of July 2018
Table 3.11-5 Registration information of isopyrazam in China, as of July 2018
Table 3.11-6 Registration information of isopyrazam in France, as of July 2018
Table 3.11-7 Registration information of isopyrazam in Greece, as of July 2018
Table 3.11-8 Registration information of isopyrazam in the Netherlands, as of July 2018
Table 3.11-9 Registration information of isopyrazam in Uruguay, as of July 2018
Table 3.12-1 Patent information of sedaxane in some countries/regions, as of July 2018
Table 3.12-2 Registration information of sedaxane in Argentina, as of July 2018
Table 3.12-3 Registration information of sedaxane in Australia, as of July 2018
Table 3.12-4 Registration information of sedaxane in Canada, as of July 2018
Table 3.12-5 Registration information of sedaxane in Chile, as of July 2018
Table 3.12-6 Registration information of sedaxane in China, as of July 2018
Table 3.12-7 Registration information of sedaxane in Denmark, as of July 2018
Table 3.12-8 Registration information of sedaxane in Finland, as of July 2018
Table 3.12-9 Registration information of sedaxane in France, as of July 2018
Table 3.12-10 Registration information of sedaxane in Greece, as of July 2018
Table 3.12-11 Registration information of sedaxane in Uruguay, as of July 2018
Table 4.1-1 Patent information of cyprosulfamide in some countries/regions, as of July 2018
Table 4.1-2 Registration information of cyprosulfamide in Belgium, as of July 2018
Table 4.1-3 Registration information of cyprosulfamide in Canada, as of July 2018
Table 4.1-4 Registration information of cyprosulfamide in Argentina, as of July 2018
Table 4.1-5 Registration information of cyprosulfamide in the Netherlands, as of July 2018

List of Figures

Figure 1.1-1 Chemical structure of aminopyralid
Figure 1.2-1 Chemical structure of flucetosulfuron
Figure 1.2-2 Route for synthesizing flucetosulfuron
Figure 1.3-1 Chemical structure of flufenpyr-ethyl
Figure 1.3-2 Route for synthesizing flufenpyr-ethyl
Figure 1.4-1 Chemical structure of metamifop
Figure 1.4-2 Route A for synthesizing metamifop
Figure 1.4-3 Route B for synthesizing metamifop
Figure 1.4-4 Route C for synthesizing metamifop
Figure 1.5-1 Chemical structure of orthosulfamuron
Figure 1.5-2 Route A for synthesizing orthosulfamuron
Figure 1.5-3 Route B for synthesizing orthosulfamuron
Figure 1.6-1 Chemical structure of pinoxaden
Figure 1.6-2 Route for synthesizing pinoxaden
Figure 1.7-1 Chemical structure of pyrasulfotole
Figure 1.8-1 Chemical structure of Pyroxasulfone
Figure 1.9-1 Chemical structure of pyroxsulam
Figure 1.10-1 Chemical structure of saflufenacil
Figure 1.11-1 Chemical structure of tembotrione
Figure 1.11-2 Route for synthesizing tembotrione
Figure 1.12-1 Chemical structure of thiencarbazone-methyl
Figure 1.13-1 Chemical structure of topramezone
Figure 1.13-2 Route for synthesizing topramezone
Figure 2.1-1 Chemical structure of chlorantraniliprole
Figure 2.2-1 Chemical structure of flubendiamide
Figure 2.3-1 Chemical structure of metofluthrin
Figure 2.3-2 Route for synthesizing metofluthrin
Figure 2.4-1 Chemical structure of pyrifluquinazon
Figure 2.5-1 Chemical structure of spirotetramat
Figure 2.5-2 Route for synthesizing spirotetramat
Figure 2.6-1 Chemical structure of cyantraniliprole
Figure 2.7-1 Chemistry structure of cyflumetofen
Figure 3.1-1 Chemical structure of amisulbrom
Figure 3.2-1 Chemical structure of fenpyrazamine
Figure 3.3-1 Chemical structure of fluopicolide
Figure 3.3-2 Route A for synthesizing fluopicolide
Figure 3.3-3 Route B for synthesizing fluopicolide
Figure 3.4-1 Chemical structure of isotianil
Figure 3.4-2 Route for synthesizing isotianil
Figure 3.5-1 Chemical structure of mandipropamid
Figure 3.6-1 Chemical structure of metrafenone
Figure 3.6-2 Route for synthesizing metrafenone
Figure 3.7-1 Chemical structure of penflufen
Figure 3.8-1 Chemical structure of valifenalate
Figure 3.9-1 Chemical structure of bixafen
Figure 3.10-1 Chemical structure of fluopyram
Figure 3.11-1 Chemical structure of isopyrazam
Figure 3.12-1 Chemical structure of sedaxane
Figure 4.1-1 Chemical structure of cyprosulfamide

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Trifluralin Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 96

Trifluralin is a yellow-orange crystalline solid. Denser than water and not soluble in water. Hence sinks in water. Melting point 48.5-49°C. Used as a selective pre-emergence herbicide. The global Trifluralin market was valued at US$ 170 million in 2023 and is anticipated to reach US$ 215.4 million by 2030, witnessing a CAGR of 3.4% during The forecast period 2024-2030. Regionally, The production areas of Trifluralin are concentrated in USA, China and EU. China is The biggest......

Global Dithiocarbamate Fungicides Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 99

Dithiocarbamate fungicides are a group of non-systemic (surface acting) fungicides. EBDCs active ingredients approved for use are mancozeb, thiram, propineb and others. The most EBDC usage is mancozeb. The global Dithiocarbamate Fungicides market was valued at US$ 920.3 million in 2023 and is anticipated to reach US$ 1097.2 million by 2030, witnessing a CAGR of 2.5% during The forecast period 2024-2030. India is The largest market with about 33% market share. Followed by Euro......

Global Elemental Sulphur Based Pesticides Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 117

According to our LPI (LP Information) latest study, the global Elemental Sulphur Based Pesticides market size was valued at US$ 78 million in 2023. With growing demand in downstream market, the Elemental Sulphur Based Pesticides is forecast to a readjusted size of US$ 166.7 million by 2030 with a CAGR of 11.4% during review period. The research report highlights the growth potential of the global Elemental Sulphur Based Pesticides market. Elemental Sulphur Based Pesticides are expected t......

Global Cypermethrin Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 113

According to our LPI (LP Information) latest study, the global Cypermethrin market size was valued at US$ 183.1 million in 2023. With growing demand in downstream market, the Cypermethrin is forecast to a readjusted size of US$ 253.7 million by 2030 with a CAGR of 4.8% during review period. The research report highlights the growth potential of the global Cypermethrin market. Cypermethrin are expected to show stable growth in the future market. However, product differentiation, reducing ......

Global Synthetic Pyrethroids Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 114

According to our LPI (LP Information) latest study, the global Synthetic Pyrethroids market size was valued at US$ 2001.5 million in 2023. With growing demand in downstream market, the Synthetic Pyrethroids is forecast to a readjusted size of US$ 2679.1 million by 2030 with a CAGR of 4.3% during review period. The research report highlights the growth potential of the global Synthetic Pyrethroids market. Synthetic Pyrethroids are expected to show stable growth in the future market. Howev......

Global Carbofuran Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 93

According to our LPI (LP Information) latest study, the global Carbofuran market size was valued at US$ 40 million in 2023. With growing demand in downstream market, the Carbofuran is forecast to a readjusted size of US$ 28 million by 2030 with a CAGR of -5.1% during review period. The research report highlights the growth potential of the global Carbofuran market. Carbofuran are expected to show stable growth in the future market. However, product differentiation, reducing costs, and su......

Global Florasulam Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 92

According to our LPI (LP Information) latest study, the global Florasulam market size was valued at US$ 320.9 million in 2023. With growing demand in downstream market, the Florasulam is forecast to a readjusted size of US$ 661.7 million by 2030 with a CAGR of 10.9% during review period. The research report highlights the growth potential of the global Florasulam market. Florasulam are expected to show stable growth in the future market. However, product differentiation, reducing costs, ......

Global Bioherbicide Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94

According to our LPI (LP Information) latest study, the global Bioherbicide market size was valued at US$ 46 million in 2023. With growing demand in downstream market, the Bioherbicide is forecast to a readjusted size of US$ 93 million by 2030 with a CAGR of 10.6% during review period. The research report highlights the growth potential of the global Bioherbicide market. Bioherbicide are expected to show stable growth in the future market. However, product differentiation, reducing costs......

Global Rodenticide Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 127

According to our LPI (LP Information) latest study, the global Rodenticide market size was valued at US$ 1337.3 million in 2023. With growing demand in downstream market, the Rodenticide is forecast to a readjusted size of US$ 1777.5 million by 2030 with a CAGR of 4.1% during review period. The research report highlights the growth potential of the global Rodenticide market. Rodenticide are expected to show stable growth in the future market. However, product differentiation, reducing co......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs